March 
13th
 at 
6:00pm
Weill Women Innovators

Caption

Sponsors Block #3

Image Grid Block #4



Sponsors Block #2

December 
10
 at 
5:00pm
Weill Women Innovators
RSVP to receive webinar link
Text goes here
X

Inventors and innovators wanted!

Do you have an idea for a medical device but aren’t sure what to do next or how to produce it? Join us in the brand-new BioVenture eLab for an exciting evening to discuss medical device innovation as we begin a new initiative to gather like-minded individuals interested in the field.

 

All backgrounds are encouraged to attend: i.e., surgeons, clinicians, researchers, business, graduate students, engineers etc.

Dr. Srivastava is an experienced biotechnology executive and investment analyst. Dr. Srivastava was recently the Chief Financial and Strategy Officer for Abide Therapeutics. Prior to this, she was the Chief Financial and Strategy Officer for Intellia Therapeutics from April 2015 to December 2016. She played an integral role in helping start up Intellia’s financial operations and strategic direction, the Series B private funding, and the initial public offering.

Dr. Srivastava has fifteen years of experience as a stock analyst for biotechnology sector on Wall Street. She was the senior analyst and team leader of the biotechnology group at Goldman Sachs. Prior to that role, Dr. Srivastava was the senior biotechnology analyst at Morgan Stanley and ThinkEquity Partners, LLC, and began her career as a research associate at JP Morgan. Dr. Srivastava has also served as an independent strategy advisor to several high growth potential, therapeutic focused, biotechnology companies.

Dr. Srivastava received her PhD in neuroscience from New York University and her B.Sc from St. Xavier’s College in India.

Text Block #11

Starting your own business and picking the right niche in no time

Dr. Srivastava is an experienced biotechnology executive and investment analyst. Dr. Srivastava was recently the Chief Financial and Strategy Officer for Abide Therapeutics. Prior to this, she was the Chief Financial and Strategy Officer for Intellia Therapeutics from April 2015 to December 2016. She played an integral role in helping start up Intellia’s financial operations and strategic direction, the Series B private funding, and the initial public offering.

Dr. Srivastava has fifteen years of experience as a stock analyst for biotechnology sector on Wall Street. She was the senior analyst and team leader of the biotechnology group at Goldman Sachs. Prior to that role, Dr. Srivastava was the senior biotechnology analyst at Morgan Stanley and ThinkEquity Partners, LLC, and began her career as a research associate at JP Morgan. Dr. Srivastava has also served as an independent strategy advisor to several high growth potential, therapeutic focused, biotechnology companies.

Dr. Srivastava received her PhD in neuroscience from New York University and her B.Sc from St. Xavier’s College in India.

#BioVentureMedicalDeviceInnovationEvent

Text Block #1

Join us Tuesday, November 24 for a roundtable discussing healthcare entrepreneurship with entrepreneurs from JLABS @ NYC! This panel is part of the Weill Cornell Medicine Accelerating BioVenture Innovation (ABI) entrepreneurship training program that builds teams and business plans around patented technologies from Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center and Rockefeller University.

 

Speakers include:

Erika Milczek, PhD, Chief Executive Officer and Founder, Curie Co

Kwaku Owusu, MS/MBA, Founder & CEO, Drugviu

Maria Luisa Pineda, PhD, Co-founder & CEO, Envisagenics


Moderated by Stephen Pitt, PhD, Head of JLABS @ US North East

 

Tuesday, November 24, 2020

5:30-7:00PM

 

ABI is organized and sponsored by Weill Cornell Medicine’s BioVenture eLab and the Office of BioPharma Alliances & Research Collaborations.

Clear your calendar - It's going down! You're invited to take part in the festivities. Come one, come all, bring a guest, and hang loose. This is going to be epic!

Text Block #1

Starting your own business and picking the right niche in no time

We are excited to announce that Bioventure eLab, which is part of the Biopharma Alliances & Research Collaborations, is collaborating with AmplifyHer Ventures to announce a unique competition open exclusively to Weill Cornell associated companies, led or founded by a woman. Our collaborator, AmplifyHer, will make an investment of up to $50K into a startup based on a technology developed by a woman scientist, or with a female in a leadership role at the company. The winner will be announced at our Startup Symposium in late February.

 

The selection committee includes:

Tricia Black, Partner, AmplifyHer Ventures

Meghan Cross, Cornell ‘08, Partner, AmplifyHer Ventures

Howard Morgan, PhD ‘68, Chairman, B Capital Group

Scott Nolan, Cornell ‘03, MEng ‘04, Partner, Founders Fund

Beckie Robertson, Cornell ‘82, Managing Director, Versant Ventures

 

Apply here

Important Dates

Competition Announced: December 3, 2020

Applications Due: January 15, 2021

Diligence Meetings: Jan 15 - February 2021

Finalists Selected: February, 2021

Winners Notified : ~1 week before showcase

Winner Presentations at Startup Symposium: February, 2021

Share with Friends
Facebook
Twitter
LinkedIn
Link
Powered by
CONTACT THE ORGANIZER
Google   Outlook   iCal   Yahoo

RSVP

processing image...

Throwing your own event?

Make it awesome with Splash.
Check it out!
Google Icon
Google
Outlook Icon
Outlook
Apple Icon
Apple
Yahoo Icon
Yahoo